Guidant/DoJ Probe Details Postmarket Reporting Meltdown With AAA Device
This article was originally published in The Gray Sheet
Executive Summary
A settlement between Guidant and the Department of Justice over deficient medical device reporting of deaths and serious injuries, combined with public awareness of the lapses, sets the stage for closer scrutiny of MDR practices across the industry
You may also be interested in...
AAA Endografts Show Early Promise In Lowering Mortality – Lancet Study
Longer-term follow-up is needed to confirm early clinical results showing a survival benefit for patients receiving endovascular aneurysm repair versus open surgery for abdominal aortic aneurysm treatment, according to an Aug. 25 Lancet study
AAA Endografts Show Early Promise In Lowering Mortality – Lancet Study
Longer-term follow-up is needed to confirm early clinical results showing a survival benefit for patients receiving endovascular aneurysm repair versus open surgery for abdominal aortic aneurysm treatment, according to an Aug. 25 Lancet study
Guidant, Boston Scientific Stocks Weather DES Issues
Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May